|
市場調査レポート
商品コード
1292508
白血病治療薬の世界市場規模、シェア、産業動向分析レポート薬剤クラス別（標的療法・免疫療法、化学療法）、流通チャネル別、タイプ別、地域別展望・予測、2023～2029年Global Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and Chemotherapy), By Distribution Channel, By Type, By Regional Outlook and Forecast, 2023 - 2029 |
||||||
|
|
|||||||
| 白血病治療薬の世界市場規模、シェア、産業動向分析レポート薬剤クラス別（標的療法・免疫療法、化学療法）、流通チャネル別、タイプ別、地域別展望・予測、2023～2029年 |
|
出版日: 2023年05月31日
発行: KBV Research
ページ情報: 英文 236 Pages
納期: 即納可能
 |
- 全表示
- 概要
- 図表
- 目次
白血病治療薬の市場規模は、2029年までに117億米ドルに達すると予測され、予測期間中のCAGRは6.0%の市場成長率で上昇すると予想されています。
KBV Cardinalマトリックスで提示された分析によると、Pfizer, Inc.が本市場における先駆者です。2020年6月、Pfizer, Inc.は、ヘッジホッグ経路阻害剤であるDAURISMOを、化学療法の一種である低用量シタラビンと組み合わせて、成人患者の新規診断の急性骨髄性白血病（AML）治療として承認を取得しました。この承認により、Pfizer, Inc.は、欧州全域の患者に新たな治療選択肢を提供することで、がんと共に生きる人々に貢献します。AbbVie, Inc.、Bristol Myers Squibb Company、Sanofi S.A.、Gilead Sciences, Inc.などの企業が、この市場における主要なイノベーターとして挙げられます。
市場成長要因
白血病治療のための革新的な治療法
様々なタイプの白血病の治療成績を向上させるために、様々な医薬品を組み合わせた独自の治療技術を開発するために、数多くの研究プロジェクトが実施されています。例えば、化学療法は標準的な治療法ですが、化学療法にシタラビンやアントラサイクリンという医薬品を組み合わせて、患者の治療成績を向上させる新しい戦略が用いられています。化学療法に抵抗がある人が多いため、企業はこの病気を治療するための免疫治療薬を開発しています。したがって、市場開拓は、白血病患者のための最先端の診断と治療法の開発によって、予想される期間中に促進されると予想されます。
医薬品開発をサポートするバイオインフォマティクスツールの開発
製薬会社は現在、新規治療薬の発見や、決定した標的の活性を変化させることができる見込みのある新規化合物の発見に力を注いでいます。また、前臨床試験や臨床試験は、時間がかかり、価格も高く、リスクの高いものです。そのため、医薬品開発プロセスを促進するために、効率的で最先端の薬効予測方法が必要とされています。標的の特定、リードの最適化、リードの検証は、統計的アルゴリズムのようなバイオインフォマティクス技術を使用することで達成することができます。これらのツールは、医薬品開発と創薬の双方をサポートします。現在の医薬品開発ソリューションを改善するためのバイオインフォマティクスツールの使用が増加した結果、市場は拡大すると予想されます。
市場の抑制要因
白血病治療薬の副作用と厳しい規制
市場の拡大は、治療に伴う副作用や好ましくない反応によって制約を受けると予測されます。例えば化学療法は、皮膚症状、脱毛、感染症、高血圧、疲労、その他類似の副作用を引き起こします。また、治療法が異なれば、副作用の内容も異なります。例えば、吐き気、肝臓の問題、髪の色落ち、下痢、嘔吐などの類似の副作用が、標的治療によってもたらされることがあります。さらに、放射線療法を含む他の治療方法のいくつかの副作用は、白血病治療薬の採用率を低下させる可能性があります。予測期間中は、これらの要因が市場の成長を抑制すると予想されます。
タイプ別展望
タイプ別に、市場は急性リンパ性白血病、急性骨髄性白血病、慢性リンパ性白血病、慢性骨髄性白血病、その他に分類されます。2022年の市場では、慢性リンパ性白血病のセグメントが最も高い収益シェアを占めています。慢性リンパ性白血病（CLL）は、骨髄のリンパ球から血液にゆっくりと広がるがんです。このセグメントの成長に影響を与える3つの主要な動向は、あまり活動的でない生活様式の採用の加速、慢性リンパ性白血病の発生率の増加、および高齢者人口の増加です。
薬物クラスの展望
薬剤クラス別では、化学療法と標的治療・免疫療法に分類されます。2022年の市場では、標的治療・免疫療法分野が最大の収益シェアを占めています。がん細胞の特定の異常を標的とする薬物療法が使用されます。標的薬物療法は、これらの異常を妨害することによって、がん細胞を殺すことができます。がんに対抗するための免疫療法では、患者の免疫系が使用されます。がん細胞は、免疫系細胞による検出を回避するためのタンパク質を作るため、病気と戦う体の免疫系ががんを攻撃しない場合があります。免疫療法は、そのような処置を妨害することで効果を発揮します。
販売チャネルの展望
流通チャネル別に見ると、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに二分されます。オンラインプロバイダー部門は、2022年の市場においてかなりの収益シェアを獲得しました。これは、継続的なサービスや様々なソリューションが容易に利用できることに起因しています。また、eコマースの売上急増、物流サービスの向上、簡単な支払い方法なども、市場拡大の要因となっています。
地域別の展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されています。2022年、北米地域は最大の収益シェアで市場をリードしました。北米は現在、高いヘルスケア支出、白血病新薬の創製における多くの重要なプレーヤー、白血病患者の増加により、市場の主導的地位を占めています。診断クリニックや病院などの医療機関では、多くの医療機器が設置されています。製薬・バイオテクノロジー業界では、米国には世界をリードする多くの相手先ブランドメーカーが存在します。
目次
第1章 市場範囲と調査手法
- 市場の定義
- 目的
- 市場範囲
- セグメンテーション
- 調査手法
第2章 市場概要
- イントロダクション
- 概要
- 市場構成とシナリオ
- 概要
- 市場に影響を与える主な要因
- 市場促進要因
- 市場抑制要因
第3章 競合分析- 世界
- KBVカーディナルマトリックス
- 最近の業界全体の戦略的展開
- パートナーシップ、コラボレーション、および契約
- 製品の発売と製品の拡大
- 買収と合併
- 承認と証跡
- 主要成功戦略
- 主な戦略
- 主要な戦略的動き
第4章 世界の白血病治療薬市場：薬物クラス別
- 世界の標的療法および免疫療法市場：地域別
- 世界の化学療法市場：地域別
第5章 世界の白血病治療薬市場：流通チャネル別
- 世界の病院薬局市場：地域別
- 世界のドラッグストアおよび小売薬局市場：地域別
- 世界のオンラインプロバイダー市場：地域別
第6章 世界の白血病治療薬市場：タイプ別
- 世界の慢性リンパ性白血病市場：地域別
- 世界の急性リンパ性白血病市場：地域別
- 世界の慢性骨髄性白血病市場：地域別
- 世界の急性骨髄性白血病市場：地域別
- 世界のその他の市場：地域別
第7章 世界の白血病治療薬市場：地域別
- 北米
- 北米の市場：国別
- 米国
- カナダ
- メキシコ
- その他北米地域
- 北米の市場：国別
- 欧州
- 欧州の市場：国別
- ドイツ
- 英国
- フランス
- ロシア
- スペイン
- イタリア
- その他欧州地域
- 欧州の市場：国別
- アジア太平洋
- アジア太平洋の市場：国別
- 中国
- 日本
- インド
- 韓国
- シンガポール
- マレーシア
- その他アジア太平洋地域
- アジア太平洋の市場：国別
- ラテンアメリカ・中東・アフリカ
- ラテンアメリカ・中東・アフリカの市場：国別
- ブラジル
- アルゼンチン
- アラブ首長国連邦
- サウジアラビア
- 南アフリカ
- ナイジェリア
- その他ラテンアメリカ・中東・アフリカ地域
- ラテンアメリカ・中東・アフリカの市場：国別
第8章 企業プロファイル
- Gilead Sciences, Inc
- Bristol Myers Squibb Company
- Sanofi SA
- AbbVie, Inc
- Teva Pharmaceutical Industries Ltd
- Lupin Limited
- Amgen, Inc
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc
- Novartis AG
LIST OF TABLES
- TABLE 1 Global Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 2 Global Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 3 Partnerships, Collaborations and Agreements- Leukemia Therapeutics Market
- TABLE 4 Product Launches And Product Expansions- Leukemia Therapeutics Market
- TABLE 5 Acquisition and Mergers- Leukemia Therapeutics Market
- TABLE 6 Approvals & Trials- Leukemia Therapeutics Market
- TABLE 7 Global Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 8 Global Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 9 Global Targeted Therapy & Immunotherapy Market by Region, 2019 - 2022, USD Million
- TABLE 10 Global Targeted Therapy & Immunotherapy Market by Region, 2023 - 2029, USD Million
- TABLE 11 Global Chemotherapy Market by Region, 2019 - 2022, USD Million
- TABLE 12 Global Chemotherapy Market by Region, 2023 - 2029, USD Million
- TABLE 13 Global Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 14 Global Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 15 Global Hospital Pharmacies Market by Region, 2019 - 2022, USD Million
- TABLE 16 Global Hospital Pharmacies Market by Region, 2023 - 2029, USD Million
- TABLE 17 Global Drug Store & Retail Pharmacies Market by Region, 2019 - 2022, USD Million
- TABLE 18 Global Drug Store & Retail Pharmacies Market by Region, 2023 - 2029, USD Million
- TABLE 19 Global Online Providers Market by Region, 2019 - 2022, USD Million
- TABLE 20 Global Online Providers Market by Region, 2023 - 2029, USD Million
- TABLE 21 Global Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 22 Global Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 23 Global Chronic Lymphocytic Leukemia Market by Region, 2019 - 2022, USD Million
- TABLE 24 Global Chronic Lymphocytic Leukemia Market by Region, 2023 - 2029, USD Million
- TABLE 25 Global Acute Lymphocytic Leukemia Market by Region, 2019 - 2022, USD Million
- TABLE 26 Global Acute Lymphocytic Leukemia Market by Region, 2023 - 2029, USD Million
- TABLE 27 Global Chronic Myeloid Leukemia Market by Region, 2019 - 2022, USD Million
- TABLE 28 Global Chronic Myeloid Leukemia Market by Region, 2023 - 2029, USD Million
- TABLE 29 Global Acute Myeloid Leukemia Market by Region, 2019 - 2022, USD Million
- TABLE 30 Global Acute Myeloid Leukemia Market by Region, 2023 - 2029, USD Million
- TABLE 31 Global Others Market by Region, 2019 - 2022, USD Million
- TABLE 32 Global Others Market by Region, 2023 - 2029, USD Million
- TABLE 33 Global Leukemia Therapeutics Market by Region, 2019 - 2022, USD Million
- TABLE 34 Global Leukemia Therapeutics Market by Region, 2023 - 2029, USD Million
- TABLE 35 North America Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 36 North America Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 37 North America Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 38 North America Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 39 North America Targeted Therapy & Immunotherapy Market by Country, 2019 - 2022, USD Million
- TABLE 40 North America Targeted Therapy & Immunotherapy Market by Country, 2023 - 2029, USD Million
- TABLE 41 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
- TABLE 42 North America Chemotherapy Market by Country, 2023 - 2029, USD Million
- TABLE 43 North America Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 44 North America Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 45 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 46 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
- TABLE 47 North America Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 48 North America Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
- TABLE 49 North America Online Providers Market by Country, 2019 - 2022, USD Million
- TABLE 50 North America Online Providers Market by Country, 2023 - 2029, USD Million
- TABLE 51 North America Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 52 North America Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 53 North America Chronic Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 54 North America Chronic Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 55 North America Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 56 North America Acute Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 57 North America Chronic Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 58 North America Chronic Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 59 North America Acute Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 60 North America Acute Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 61 North America Others Market by Country, 2019 - 2022, USD Million
- TABLE 62 North America Others Market by Country, 2023 - 2029, USD Million
- TABLE 63 North America Leukemia Therapeutics Market by Country, 2019 - 2022, USD Million
- TABLE 64 North America Leukemia Therapeutics Market by Country, 2023 - 2029, USD Million
- TABLE 65 US Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 66 US Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 67 US Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 68 US Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 69 US Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 70 US Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 71 US Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 72 US Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 73 Canada Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 74 Canada Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 75 Canada Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 76 Canada Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 77 Canada Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 78 Canada Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 79 Canada Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 80 Canada Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 81 Mexico Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 82 Mexico Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 83 Mexico Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 84 Mexico Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 85 Mexico Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 86 Mexico Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 87 Mexico Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 88 Mexico Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 89 Rest of North America Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 90 Rest of North America Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 91 Rest of North America Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 92 Rest of North America Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 93 Rest of North America Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 94 Rest of North America Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 95 Rest of North America Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 96 Rest of North America Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 97 Europe Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 98 Europe Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 99 Europe Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 100 Europe Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 101 Europe Targeted Therapy & Immunotherapy Market by Country, 2019 - 2022, USD Million
- TABLE 102 Europe Targeted Therapy & Immunotherapy Market by Country, 2023 - 2029, USD Million
- TABLE 103 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
- TABLE 104 Europe Chemotherapy Market by Country, 2023 - 2029, USD Million
- TABLE 105 Europe Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 106 Europe Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 107 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 108 Europe Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
- TABLE 109 Europe Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 110 Europe Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
- TABLE 111 Europe Online Providers Market by Country, 2019 - 2022, USD Million
- TABLE 112 Europe Online Providers Market by Country, 2023 - 2029, USD Million
- TABLE 113 Europe Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 114 Europe Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 115 Europe Chronic Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 116 Europe Chronic Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 117 Europe Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 118 Europe Acute Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 119 Europe Chronic Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 120 Europe Chronic Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 121 Europe Acute Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 122 Europe Acute Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 123 Europe Others Market by Country, 2019 - 2022, USD Million
- TABLE 124 Europe Others Market by Country, 2023 - 2029, USD Million
- TABLE 125 Europe Leukemia Therapeutics Market by Country, 2019 - 2022, USD Million
- TABLE 126 Europe Leukemia Therapeutics Market by Country, 2023 - 2029, USD Million
- TABLE 127 Germany Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 128 Germany Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 129 Germany Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 130 Germany Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 131 Germany Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 132 Germany Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 133 Germany Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 134 Germany Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 135 UK Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 136 UK Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 137 UK Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 138 UK Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 139 UK Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 140 UK Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 141 UK Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 142 UK Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 143 France Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 144 France Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 145 France Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 146 France Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 147 France Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 148 France Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 149 France Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 150 France Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 151 Russia Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 152 Russia Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 153 Russia Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 154 Russia Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 155 Russia Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 156 Russia Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 157 Russia Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 158 Russia Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 159 Spain Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 160 Spain Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 161 Spain Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 162 Spain Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 163 Spain Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 164 Spain Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 165 Spain Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 166 Spain Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 167 Italy Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 168 Italy Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 169 Italy Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 170 Italy Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 171 Italy Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 172 Italy Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 173 Italy Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 174 Italy Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 175 Rest of Europe Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 176 Rest of Europe Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 177 Rest of Europe Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 178 Rest of Europe Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 179 Rest of Europe Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 180 Rest of Europe Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 181 Rest of Europe Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 182 Rest of Europe Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 183 Asia Pacific Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 184 Asia Pacific Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 185 Asia Pacific Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 186 Asia Pacific Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 187 Asia Pacific Targeted Therapy & Immunotherapy Market by Country, 2019 - 2022, USD Million
- TABLE 188 Asia Pacific Targeted Therapy & Immunotherapy Market by Country, 2023 - 2029, USD Million
- TABLE 189 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
- TABLE 190 Asia Pacific Chemotherapy Market by Country, 2023 - 2029, USD Million
- TABLE 191 Asia Pacific Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 192 Asia Pacific Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 193 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 194 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
- TABLE 195 Asia Pacific Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 196 Asia Pacific Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
- TABLE 197 Asia Pacific Online Providers Market by Country, 2019 - 2022, USD Million
- TABLE 198 Asia Pacific Online Providers Market by Country, 2023 - 2029, USD Million
- TABLE 199 Asia Pacific Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 200 Asia Pacific Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 201 Asia Pacific Chronic Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 202 Asia Pacific Chronic Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 203 Asia Pacific Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 204 Asia Pacific Acute Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 205 Asia Pacific Chronic Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 206 Asia Pacific Chronic Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 207 Asia Pacific Acute Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 208 Asia Pacific Acute Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 209 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
- TABLE 210 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
- TABLE 211 Asia Pacific Leukemia Therapeutics Market by Country, 2019 - 2022, USD Million
- TABLE 212 Asia Pacific Leukemia Therapeutics Market by Country, 2023 - 2029, USD Million
- TABLE 213 China Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 214 China Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 215 China Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 216 China Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 217 China Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 218 China Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 219 China Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 220 China Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 221 Japan Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 222 Japan Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 223 Japan Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 224 Japan Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 225 Japan Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 226 Japan Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 227 Japan Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 228 Japan Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 229 India Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 230 India Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 231 India Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 232 India Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 233 India Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 234 India Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 235 India Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 236 India Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 237 South Korea Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 238 South Korea Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 239 South Korea Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 240 South Korea Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 241 South Korea Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 242 South Korea Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 243 South Korea Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 244 South Korea Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 245 Singapore Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 246 Singapore Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 247 Singapore Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 248 Singapore Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 249 Singapore Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 250 Singapore Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 251 Singapore Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 252 Singapore Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 253 Malaysia Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 254 Malaysia Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 255 Malaysia Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 256 Malaysia Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 257 Malaysia Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 258 Malaysia Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 259 Malaysia Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 260 Malaysia Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 261 Rest of Asia Pacific Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 262 Rest of Asia Pacific Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 263 Rest of Asia Pacific Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 264 Rest of Asia Pacific Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 265 Rest of Asia Pacific Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 266 Rest of Asia Pacific Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 267 Rest of Asia Pacific Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 268 Rest of Asia Pacific Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 269 LAMEA Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 270 LAMEA Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 271 LAMEA Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 272 LAMEA Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 273 LAMEA Targeted Therapy & Immunotherapy Market by Country, 2019 - 2022, USD Million
- TABLE 274 LAMEA Targeted Therapy & Immunotherapy Market by Country, 2023 - 2029, USD Million
- TABLE 275 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
- TABLE 276 LAMEA Chemotherapy Market by Country, 2023 - 2029, USD Million
- TABLE 277 LAMEA Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 278 LAMEA Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 279 LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 280 LAMEA Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
- TABLE 281 LAMEA Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 282 LAMEA Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
- TABLE 283 LAMEA Online Providers Market by Country, 2019 - 2022, USD Million
- TABLE 284 LAMEA Online Providers Market by Country, 2023 - 2029, USD Million
- TABLE 285 LAMEA Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 286 LAMEA Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 287 LAMEA Chronic Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 288 LAMEA Chronic Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 289 LAMEA Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 290 LAMEA Acute Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 291 LAMEA Chronic Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 292 LAMEA Chronic Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 293 LAMEA Acute Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
- TABLE 294 LAMEA Acute Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
- TABLE 295 LAMEA Others Market by Country, 2019 - 2022, USD Million
- TABLE 296 LAMEA Others Market by Country, 2023 - 2029, USD Million
- TABLE 297 LAMEA Leukemia Therapeutics Market by Country, 2019 - 2022, USD Million
- TABLE 298 LAMEA Leukemia Therapeutics Market by Country, 2023 - 2029, USD Million
- TABLE 299 Brazil Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 300 Brazil Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 301 Brazil Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 302 Brazil Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 303 Brazil Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 304 Brazil Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 305 Brazil Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 306 Brazil Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 307 Argentina Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 308 Argentina Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 309 Argentina Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 310 Argentina Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 311 Argentina Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 312 Argentina Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 313 Argentina Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 314 Argentina Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 315 UAE Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 316 UAE Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 317 UAE Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 318 UAE Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 319 UAE Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 320 UAE Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 321 UAE Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 322 UAE Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 323 Saudi Arabia Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 324 Saudi Arabia Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 325 Saudi Arabia Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 326 Saudi Arabia Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 327 Saudi Arabia Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 328 Saudi Arabia Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 329 Saudi Arabia Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 330 Saudi Arabia Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 331 South Africa Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 332 South Africa Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 333 South Africa Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 334 South Africa Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 335 South Africa Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 336 South Africa Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 337 South Africa Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 338 South Africa Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 339 Nigeria Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 340 Nigeria Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 341 Nigeria Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 342 Nigeria Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 343 Nigeria Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 344 Nigeria Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 345 Nigeria Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 346 Nigeria Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 347 Rest of LAMEA Leukemia Therapeutics Market, 2019 - 2022, USD Million
- TABLE 348 Rest of LAMEA Leukemia Therapeutics Market, 2023 - 2029, USD Million
- TABLE 349 Rest of LAMEA Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
- TABLE 350 Rest of LAMEA Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
- TABLE 351 Rest of LAMEA Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 352 Rest of LAMEA Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
- TABLE 353 Rest of LAMEA Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
- TABLE 354 Rest of LAMEA Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
- TABLE 355 Key Information - Gilead Sciences, Inc.
- TABLE 356 Key Information - Bristol Myers Squibb Company
- TABLE 357 Key Information - Sanofi S.A.
- TABLE 358 Key information - AbbVie, Inc.
- TABLE 359 Key Information - Teva Pharmaceuticals Industries Ltd.
- TABLE 360 Key Information - Lupin Limited
- TABLE 361 Key Information - Amgen, Inc.
- TABLE 362 Key Information - Takeda Pharmaceutical Company Limited
- TABLE 363 Key Information - Pfizer, Inc.
- TABLE 364 Key Information - Novartis AG
List of Figures
- FIG 1 Methodology for the research
- FIG 2 KBV Cardinal Matrix
- FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
- FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May - 2022, Dec) Leading Players
- FIG 5 Global Leukemia Therapeutics Market Share by Drug Class, 2022
- FIG 6 Global Leukemia Therapeutics Market Share by Drug Class, 2029
- FIG 7 Global Leukemia Therapeutics Market by Drug Class, 2019 - 2029, USD Million
- FIG 8 Global Leukemia Therapeutics Market Share by Distribution Channel, 2022
- FIG 9 Global Leukemia Therapeutics Market Share by Distribution Channel, 2029
- FIG 10 Global Leukemia Therapeutics Market by Distribution Channel, 2019 - 2029, USD Million
- FIG 11 Global Leukemia Therapeutics Market Share by Type, 2022
- FIG 12 Global Leukemia Therapeutics Market Share by Type, 2029
- FIG 13 Global Leukemia Therapeutics Market by Type, 2019 - 2029, USD Million
- FIG 14 Global Leukemia Therapeutics Market Share by Region, 2022
- FIG 15 Global Leukemia Therapeutics Market Share by Region, 2029
- FIG 16 Global Leukemia Therapeutics Market by Region, 2019 - 2029, USD Million
- FIG 17 Recent strategies and developments: Gilead Sciences, Inc.
- FIG 18 Recent strategies and developments: Bristol Myers Squibb Company
- FIG 19 Recent strategies and developments: Sanofi S.A.
The Global Leukemia Therapeutics Market size is expected to reach $11.7 billion by 2029, rising at a market growth of 6.0% CAGR during the forecast period.
Chronic lymphocytic leukemia (CLL) is the major contributor to the market because of the growing older population. Thus, it is expected to generate approximately $4,834.8 million revenue of the total market by 2029. One in six deaths, or 9.6 million, was attributed to cancer in 2018, making it the second largest cause of death worldwide. For example, in the US, CLL accounts for 25 to 30% of all cases of leukemia. The American Cancer Society predicted that in the year 2020, there would be roughly 21,040 new cases of CLL and about 4,060 fatalities. CLL/SLL is responsible for 191,000 cases and 61,000 deaths annually. Adults as young as 30 years old can develop CLL. However, people over the age of 70 are most likely to experience it. Children with CLL are incredibly uncommon. It is well known that the incidence rises quickly with age.
The major strategies followed by the market participants are partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In October, 2022, Gilead joined hands with MacroGenics to develop and commercialize advanced monoclonal antibody-based therapeutics for the treatment of cancer. Under this collaboration, both companies would develop MGD024, an investigational, bispecific antibody that binds CD3 and CD123 utilizing MacroGenics' DART® platform. Additionally, In October, 2022, Bristol Myers Squibb signed an agreement with Century Therapeutics to develop and supply up to 4 induced pluripotent stems cell-derived, engineered natural killer cell and T cell programs for hematologic malignancies and solid tumors.
Based on the Analysis presented in the KBV Cardinal matrix; Pfizer, Inc. is the forerunner in the Market. In June, 2020, Pfizer, Inc. received approval from DAURISMO, a Hedgehog pathway inhibitor, combined with low-dose cytarabine, a chemotherapy type, for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients. Through this approval, Pfizer would serve people living with cancers by providing a new treatment option for certain patients across Europe. Companies such as AbbVie, Inc., Bristol Myers Squibb Company, Sanofi S.A. and Gilead Sciences, Inc. are some of the key innovators in Market.
Market Growth Factors
Innovative therapies for leukemia treatments
Numerous research projects are being carried out to create distinct therapeutic techniques that combine diverse medicines to boost patient outcomes for various leukemia types. For example, although chemotherapy is the standard of care, a new strategy is being used that combines chemotherapy with the medicines cytarabine and anthracyclines to enhance patient outcomes. Because many people resist several chemotherapy medications, businesses are creating immune treatments to treat this illness. Therefore, market growth is anticipated to be boosted by the development of such cutting-edge diagnostics and therapies for leukemia patients during the anticipated period.
Developing bioinformatics tool to support drug development
Pharmaceutical companies are currently concentrating their efforts on finding novel therapeutic agents and prospective new compounds that can alter the activity of the determined target. Additionally, preclinical, and clinical studies are a drawn-out, frequently pricey, and risky procedure. To boost the drug development process, an efficient and cutting-edge method of predicting drug efficacy is therefore required. Target identification, lead optimization, and lead validation can all be accomplished with the use of bioinformatic technologies like statistical algorithms. These tools support both drug development and drug discovery. The market is anticipated to expand as a result of the increasing use of a bioinformatics tool for improving current drug development solutions.
Market Restraining Factors
Side Effects of leukemia therapeutics and strict regulations
The expansion of the market is projected to be constrained by the side effects and unfavorable responses associated with the treatments. Chemotherapy, for example, causes side effects, including skin conditions, hair loss, infections, high blood pressure, fatigue, and other similar side effects. Different therapies also have different adverse reactions. For example, similar side events, like nausea, liver issues, hair color loss, diarrhea, and vomiting, can be brought on by targeted therapy. Additionally, some side effects of other treatment modalities, including radiotherapy, may reduce the rate at which leukemia therapeutic agents are adopted. During the forecast period, these factors are expected to restrain market growth.
Type Outlook
Based on type, the market is segmented into acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and others. In 2022, the chronic lymphocytic leukemia segment held the highest revenue share in the market. Chronic lymphocytic leukemia (CLL) is a cancer that spreads slowly from lymphocytes in the bone marrow to the blood. The three main trends influencing the segment's growth are the accelerated adoption of a less active way of life, an increasing incidence of chronic lymphocytic leukemia, and the growing elderly population.
Drug Class Outlook
By drug class, the market is fragmented into chemotherapy, and targeted therapy & immunotherapy. The targeted therapy & immunotherapy segment witnessed the largest revenue share in the market in 2022. Drug therapies that target specific abnormalities in cancer cells are used. Targeted medication therapies can kill cancer cells by obstructing these aberrations. The patient's immune system is used in immunotherapy to combat cancer. Cancer cells create proteins that assist them evade detection by immune system cells, thus the body's immune system that fights disease may not attack the cancer. Immunotherapy works by obstructing that procedure.
Distribution Channel Outlook
On the basis of distribution channel, the market is bifurcated into hospital pharmacies, drug store & retail pharmacies and online providers. The online providers segment acquired a substantial revenue share in the market in 2022. This is due to ongoing services and various solutions being readily available. In addition, the market's expansion is also fueled by a surge in e-commerce sales, better logistical services, and simple payment options.
Regional Outlook
Region wise, the market is analyzed across North America, Europe, Asia Pacific and LAMEA. In 2022, the North America region led the market with the maximum revenue share. North America now holds a leading position in the market due to high healthcare spending, many significant players in creating new leukemia medicines, and an increasing number of leukemia patients. Diagnostic clinics, hospitals, and other medical institutions have a lot of medical equipment installed. In the pharmaceutical & biotechnology industries, the United States is home to many original equipment manufacturers that lead the world.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Gilead Sciences, Inc., Bristol Myers Squibb Company, Sanofi S.A., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Lupin Limited, Amgen, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc. and Novartis AG.
Recent Strategies Deployed in Leukemia Therapeutics Market
Partnerships, Collaborations and Agreements:
Dec-2022: Sanofi signed an agreement with Innate Pharma SA, a clinical-stage oncology-focused biotech company, for natural killer cell therapeutics in oncology. Under this agreement, Sanofi would develop, manufacture, and commercialize products resulting from the research collaboration.
Dec-2022: Gilead collaborated with ImmunoGen, Inc., a pioneer in broadening the field of antibody-drug conjugates (ADCs) for the treatment of cancer. This collaboration aims to evaluate the safety and anti-leukemia activity of pivekimab sunirine in combination with magrolimab, a potential, first-in-class, investigational CD47 inhibitor.
Oct-2022: Gilead joined hands with MacroGenics, a biopharmaceutical company engaged in the development and commercialization of advanced monoclonal antibody-based therapeutics for the treatment of cancer. Under this collaboration, both companies would develop MGD024, an investigational, bispecific antibody that binds CD3 and CD123 utilizing MacroGenics' DART® platform.
Oct-2022: Bristol Myers Squibb signed an agreement with Century Therapeutics, a biotechnology company. This agreement aims to develop and supply up to 4 induced pluripotent stems cell-derived, engineered natural killer cell and T cell programs for hematologic malignancies and solid tumors.
Mar-2022: Novartis came into an agreement with Carisma Therapeutics, a biopharmaceutical pioneer in macrophage-based therapeutics. Under this agreement, companies would aim to manufacture the HER 2 targeted CAR-M cell therapy, that is tested in initial trials for the treatment of solid tumors.
Mergers & Acquisitions:
Feb-2023: Kite, a Gilead Company, acquired Tmunity Therapeutics, a clinical-stage, biotech company specializing in next-generation CAR T-therapies and technologies. This acquisition aligns with Kite's available in-house cell therapy research capabilities by adding additional licensing agreements, pipeline assets, and platform capabilities.
Aug-2022: Bristol Myers Squibb acquired Turning Point Therapeutics, Inc., a clinical-stage precision oncology company. Following this acquisition, Bristol Myers Squibb strengthened its oncology franchise through Turning Point's precision oncology franchise.
Nov-2021: Pfizer, Inc. took over Trillium Therapeutics, a clinical-stage immuno-oncology company engaged in the development of advanced therapies for the treatment of cancer. This acquisition improves Pfizer's Oncology offerings with the addition of next-generation, investigational immuno-therapeutics for haematological malignancies.
Apr-2021: Sanofi acquired Kiadis, a clinical-stage company developing cell-based immunotherapy products. Following this acquisition, the Kiadis 'off-the-shelf' K-NK cell technology platform would have wide applications compared to solid and liquid tumors.
Product Launches and Product Expansions:
Mar-2022: Teva Pharmaceuticals, a U.S.-based affiliate of Teva Pharmaceutical Industries Ltd., introduced Revlimid, the generic version of lenalidomide capsules. This launch offers patients with another key treatment option for highly challenging conditions.
Approvals & Trials:
Oct-2021: Novartis got FDA approval for Scemblix, a provider of the much-required new option for patients with chronic myeloid leukemia. The Scemblix serves patients who suffer from inadequate or intolerance response after no less than two earlier tyrosine kinase inhibitor (TKI) treatments.
Sep-2021: Takeda Pharmaceutical Company Limited received FDA approval for EXKIVITY, an Oral Therapy specifically developed for patients with EGFR Exon20 Insertion+ NSCLC. The approval unveiled an effective treatment option for patients with EGFR Exon20 insertion+ NSCLC, fulfilling an urgent requirement for difficult-to-treat cancer.
Jun-2021: Bristol Myers Squibb received European Commission approval for Onureg, a maintenance therapy in adult patients with acute myeloid leukemia. Onureg is the only, once-daily frontline oral maintenance therapy in the European Union for patients with a wide range of acute myeloid leukemia (AML) subtypes.
Scope of the Study
Market Segments covered in the Report:
By Drug Class
- Targeted Therapy & Immunotherapy
- Chemotherapy
By Distribution Channel
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Providers
By Type
- Chronic Lymphocytic Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Acute Myeloid Leukemia
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Gilead Sciences, Inc.
- Bristol Myers Squibb Company
- Sanofi S.A.
- AbbVie, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Lupin Limited
- Amgen, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Novartis AG
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Global Leukemia Therapeutics Market, by Drug Class
- 1.4.2 Global Leukemia Therapeutics Market, by Distribution Channel
- 1.4.3 Global Leukemia Therapeutics Market, by Type
- 1.4.4 Global Leukemia Therapeutics Market, by Geography
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition & Scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
- 3.1 KBV Cardinal Matrix
- 3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Product Launches and Product Expansions
- 3.2.3 Acquisition and Mergers
- 3.2.4 Approvals & Trails
- 3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
- 3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May - 2022, Dec) Leading Players
Chapter 4. Global Leukemia Therapeutics Market by Drug Class
- 4.1 Global Targeted Therapy & Immunotherapy Market by Region
- 4.2 Global Chemotherapy Market by Region
Chapter 5. Global Leukemia Therapeutics Market by Distribution Channel
- 5.1 Global Hospital Pharmacies Market by Region
- 5.2 Global Drug Store & Retail Pharmacies Market by Region
- 5.3 Global Online Providers Market by Region
Chapter 6. Global Leukemia Therapeutics Market by Type
- 6.1 Global Chronic Lymphocytic Leukemia Market by Region
- 6.2 Global Acute Lymphocytic Leukemia Market by Region
- 6.3 Global Chronic Myeloid Leukemia Market by Region
- 6.4 Global Acute Myeloid Leukemia Market by Region
- 6.5 Global Others Market by Region
Chapter 7. Global Leukemia Therapeutics Market by Region
- 7.1 North America Leukemia Therapeutics Market
- 7.1.1 North America Leukemia Therapeutics Market by Drug Class
- 7.1.1.1 North America Targeted Therapy & Immunotherapy Market by Country
- 7.1.1.2 North America Chemotherapy Market by Country
- 7.1.2 North America Leukemia Therapeutics Market by Distribution Channel
- 7.1.2.1 North America Hospital Pharmacies Market by Country
- 7.1.2.2 North America Drug Store & Retail Pharmacies Market by Country
- 7.1.2.3 North America Online Providers Market by Country
- 7.1.3 North America Leukemia Therapeutics Market by Type
- 7.1.3.1 North America Chronic Lymphocytic Leukemia Market by Country
- 7.1.3.2 North America Acute Lymphocytic Leukemia Market by Country
- 7.1.3.3 North America Chronic Myeloid Leukemia Market by Country
- 7.1.3.4 North America Acute Myeloid Leukemia Market by Country
- 7.1.3.5 North America Others Market by Country
- 7.1.4 North America Leukemia Therapeutics Market by Country
- 7.1.4.1 US Leukemia Therapeutics Market
- 7.1.4.1.1 US Leukemia Therapeutics Market by Drug Class
- 7.1.4.1.2 US Leukemia Therapeutics Market by Distribution Channel
- 7.1.4.1.3 US Leukemia Therapeutics Market by Type
- 7.1.4.2 Canada Leukemia Therapeutics Market
- 7.1.4.2.1 Canada Leukemia Therapeutics Market by Drug Class
- 7.1.4.2.2 Canada Leukemia Therapeutics Market by Distribution Channel
- 7.1.4.2.3 Canada Leukemia Therapeutics Market by Type
- 7.1.4.3 Mexico Leukemia Therapeutics Market
- 7.1.4.3.1 Mexico Leukemia Therapeutics Market by Drug Class
- 7.1.4.3.2 Mexico Leukemia Therapeutics Market by Distribution Channel
- 7.1.4.3.3 Mexico Leukemia Therapeutics Market by Type
- 7.1.4.4 Rest of North America Leukemia Therapeutics Market
- 7.1.4.4.1 Rest of North America Leukemia Therapeutics Market by Drug Class
- 7.1.4.4.2 Rest of North America Leukemia Therapeutics Market by Distribution Channel
- 7.1.4.4.3 Rest of North America Leukemia Therapeutics Market by Type
- 7.1.4.1 US Leukemia Therapeutics Market
- 7.1.1 North America Leukemia Therapeutics Market by Drug Class
- 7.2 Europe Leukemia Therapeutics Market
- 7.2.1 Europe Leukemia Therapeutics Market by Drug Class
- 7.2.1.1 Europe Targeted Therapy & Immunotherapy Market by Country
- 7.2.1.2 Europe Chemotherapy Market by Country
- 7.2.2 Europe Leukemia Therapeutics Market by Distribution Channel
- 7.2.2.1 Europe Hospital Pharmacies Market by Country
- 7.2.2.2 Europe Drug Store & Retail Pharmacies Market by Country
- 7.2.2.3 Europe Online Providers Market by Country
- 7.2.3 Europe Leukemia Therapeutics Market by Type
- 7.2.3.1 Europe Chronic Lymphocytic Leukemia Market by Country
- 7.2.3.2 Europe Acute Lymphocytic Leukemia Market by Country
- 7.2.3.3 Europe Chronic Myeloid Leukemia Market by Country
- 7.2.3.4 Europe Acute Myeloid Leukemia Market by Country
- 7.2.3.5 Europe Others Market by Country
- 7.2.4 Europe Leukemia Therapeutics Market by Country
- 7.2.4.1 Germany Leukemia Therapeutics Market
- 7.2.4.1.1 Germany Leukemia Therapeutics Market by Drug Class
- 7.2.4.1.2 Germany Leukemia Therapeutics Market by Distribution Channel
- 7.2.4.1.3 Germany Leukemia Therapeutics Market by Type
- 7.2.4.2 UK Leukemia Therapeutics Market
- 7.2.4.2.1 UK Leukemia Therapeutics Market by Drug Class
- 7.2.4.2.2 UK Leukemia Therapeutics Market by Distribution Channel
- 7.2.4.2.3 UK Leukemia Therapeutics Market by Type
- 7.2.4.3 France Leukemia Therapeutics Market
- 7.2.4.3.1 France Leukemia Therapeutics Market by Drug Class
- 7.2.4.3.2 France Leukemia Therapeutics Market by Distribution Channel
- 7.2.4.3.3 France Leukemia Therapeutics Market by Type
- 7.2.4.4 Russia Leukemia Therapeutics Market
- 7.2.4.4.1 Russia Leukemia Therapeutics Market by Drug Class
- 7.2.4.4.2 Russia Leukemia Therapeutics Market by Distribution Channel
- 7.2.4.4.3 Russia Leukemia Therapeutics Market by Type
- 7.2.4.5 Spain Leukemia Therapeutics Market
- 7.2.4.5.1 Spain Leukemia Therapeutics Market by Drug Class
- 7.2.4.5.2 Spain Leukemia Therapeutics Market by Distribution Channel
- 7.2.4.5.3 Spain Leukemia Therapeutics Market by Type
- 7.2.4.6 Italy Leukemia Therapeutics Market
- 7.2.4.6.1 Italy Leukemia Therapeutics Market by Drug Class
- 7.2.4.6.2 Italy Leukemia Therapeutics Market by Distribution Channel
- 7.2.4.6.3 Italy Leukemia Therapeutics Market by Type
- 7.2.4.7 Rest of Europe Leukemia Therapeutics Market
- 7.2.4.7.1 Rest of Europe Leukemia Therapeutics Market by Drug Class
- 7.2.4.7.2 Rest of Europe Leukemia Therapeutics Market by Distribution Channel
- 7.2.4.7.3 Rest of Europe Leukemia Therapeutics Market by Type
- 7.2.4.1 Germany Leukemia Therapeutics Market
- 7.2.1 Europe Leukemia Therapeutics Market by Drug Class
- 7.3 Asia Pacific Leukemia Therapeutics Market
- 7.3.1 Asia Pacific Leukemia Therapeutics Market by Drug Class
- 7.3.1.1 Asia Pacific Targeted Therapy & Immunotherapy Market by Country
- 7.3.1.2 Asia Pacific Chemotherapy Market by Country
- 7.3.2 Asia Pacific Leukemia Therapeutics Market by Distribution Channel
- 7.3.2.1 Asia Pacific Hospital Pharmacies Market by Country
- 7.3.2.2 Asia Pacific Drug Store & Retail Pharmacies Market by Country
- 7.3.2.3 Asia Pacific Online Providers Market by Country
- 7.3.3 Asia Pacific Leukemia Therapeutics Market by Type
- 7.3.3.1 Asia Pacific Chronic Lymphocytic Leukemia Market by Country
- 7.3.3.2 Asia Pacific Acute Lymphocytic Leukemia Market by Country
- 7.3.3.3 Asia Pacific Chronic Myeloid Leukemia Market by Country
- 7.3.3.4 Asia Pacific Acute Myeloid Leukemia Market by Country
- 7.3.3.5 Asia Pacific Others Market by Country
- 7.3.4 Asia Pacific Leukemia Therapeutics Market by Country
- 7.3.4.1 China Leukemia Therapeutics Market
- 7.3.4.1.1 China Leukemia Therapeutics Market by Drug Class
- 7.3.4.1.2 China Leukemia Therapeutics Market by Distribution Channel
- 7.3.4.1.3 China Leukemia Therapeutics Market by Type
- 7.3.4.2 Japan Leukemia Therapeutics Market
- 7.3.4.2.1 Japan Leukemia Therapeutics Market by Drug Class
- 7.3.4.2.2 Japan Leukemia Therapeutics Market by Distribution Channel
- 7.3.4.2.3 Japan Leukemia Therapeutics Market by Type
- 7.3.4.3 India Leukemia Therapeutics Market
- 7.3.4.3.1 India Leukemia Therapeutics Market by Drug Class
- 7.3.4.3.2 India Leukemia Therapeutics Market by Distribution Channel
- 7.3.4.3.3 India Leukemia Therapeutics Market by Type
- 7.3.4.4 South Korea Leukemia Therapeutics Market
- 7.3.4.4.1 South Korea Leukemia Therapeutics Market by Drug Class
- 7.3.4.4.2 South Korea Leukemia Therapeutics Market by Distribution Channel
- 7.3.4.4.3 South Korea Leukemia Therapeutics Market by Type
- 7.3.4.5 Singapore Leukemia Therapeutics Market
- 7.3.4.5.1 Singapore Leukemia Therapeutics Market by Drug Class
- 7.3.4.5.2 Singapore Leukemia Therapeutics Market by Distribution Channel
- 7.3.4.5.3 Singapore Leukemia Therapeutics Market by Type
- 7.3.4.6 Malaysia Leukemia Therapeutics Market
- 7.3.4.6.1 Malaysia Leukemia Therapeutics Market by Drug Class
- 7.3.4.6.2 Malaysia Leukemia Therapeutics Market by Distribution Channel
- 7.3.4.6.3 Malaysia Leukemia Therapeutics Market by Type
- 7.3.4.7 Rest of Asia Pacific Leukemia Therapeutics Market
- 7.3.4.7.1 Rest of Asia Pacific Leukemia Therapeutics Market by Drug Class
- 7.3.4.7.2 Rest of Asia Pacific Leukemia Therapeutics Market by Distribution Channel
- 7.3.4.7.3 Rest of Asia Pacific Leukemia Therapeutics Market by Type
- 7.3.4.1 China Leukemia Therapeutics Market
- 7.3.1 Asia Pacific Leukemia Therapeutics Market by Drug Class
- 7.4 LAMEA Leukemia Therapeutics Market
- 7.4.1 LAMEA Leukemia Therapeutics Market by Drug Class
- 7.4.1.1 LAMEA Targeted Therapy & Immunotherapy Market by Country
- 7.4.1.2 LAMEA Chemotherapy Market by Country
- 7.4.2 LAMEA Leukemia Therapeutics Market by Distribution Channel
- 7.4.2.1 LAMEA Hospital Pharmacies Market by Country
- 7.4.2.2 LAMEA Drug Store & Retail Pharmacies Market by Country
- 7.4.2.3 LAMEA Online Providers Market by Country
- 7.4.3 LAMEA Leukemia Therapeutics Market by Type
- 7.4.3.1 LAMEA Chronic Lymphocytic Leukemia Market by Country
- 7.4.3.2 LAMEA Acute Lymphocytic Leukemia Market by Country
- 7.4.3.3 LAMEA Chronic Myeloid Leukemia Market by Country
- 7.4.3.4 LAMEA Acute Myeloid Leukemia Market by Country
- 7.4.3.5 LAMEA Others Market by Country
- 7.4.4 LAMEA Leukemia Therapeutics Market by Country
- 7.4.4.1 Brazil Leukemia Therapeutics Market
- 7.4.4.1.1 Brazil Leukemia Therapeutics Market by Drug Class
- 7.4.4.1.2 Brazil Leukemia Therapeutics Market by Distribution Channel
- 7.4.4.1.3 Brazil Leukemia Therapeutics Market by Type
- 7.4.4.2 Argentina Leukemia Therapeutics Market
- 7.4.4.2.1 Argentina Leukemia Therapeutics Market by Drug Class
- 7.4.4.2.2 Argentina Leukemia Therapeutics Market by Distribution Channel
- 7.4.4.2.3 Argentina Leukemia Therapeutics Market by Type
- 7.4.4.3 UAE Leukemia Therapeutics Market
- 7.4.4.3.1 UAE Leukemia Therapeutics Market by Drug Class
- 7.4.4.3.2 UAE Leukemia Therapeutics Market by Distribution Channel
- 7.4.4.3.3 UAE Leukemia Therapeutics Market by Type
- 7.4.4.4 Saudi Arabia Leukemia Therapeutics Market
- 7.4.4.4.1 Saudi Arabia Leukemia Therapeutics Market by Drug Class
- 7.4.4.4.2 Saudi Arabia Leukemia Therapeutics Market by Distribution Channel
- 7.4.4.4.3 Saudi Arabia Leukemia Therapeutics Market by Type
- 7.4.4.5 South Africa Leukemia Therapeutics Market
- 7.4.4.5.1 South Africa Leukemia Therapeutics Market by Drug Class
- 7.4.4.5.2 South Africa Leukemia Therapeutics Market by Distribution Channel
- 7.4.4.5.3 South Africa Leukemia Therapeutics Market by Type
- 7.4.4.6 Nigeria Leukemia Therapeutics Market
- 7.4.4.6.1 Nigeria Leukemia Therapeutics Market by Drug Class
- 7.4.4.6.2 Nigeria Leukemia Therapeutics Market by Distribution Channel
- 7.4.4.6.3 Nigeria Leukemia Therapeutics Market by Type
- 7.4.4.7 Rest of LAMEA Leukemia Therapeutics Market
- 7.4.4.7.1 Rest of LAMEA Leukemia Therapeutics Market by Drug Class
- 7.4.4.7.2 Rest of LAMEA Leukemia Therapeutics Market by Distribution Channel
- 7.4.4.7.3 Rest of LAMEA Leukemia Therapeutics Market by Type
- 7.4.4.1 Brazil Leukemia Therapeutics Market
- 7.4.1 LAMEA Leukemia Therapeutics Market by Drug Class
Chapter 8. Company Profiles
- 8.1 Gilead Sciences, Inc.
- 8.1.1 Company overview
- 8.1.2 Financial Analysis
- 8.1.3 Research & Development Expenses
- 8.1.4 Recent strategies and developments:
- 8.1.4.1 Partnerships, Collaborations, and Agreements:
- 8.1.4.2 Acquisition and Mergers:
- 8.2 Bristol Myers Squibb Company
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expenses
- 8.2.5 Recent strategies and developments:
- 8.2.5.1 Acquisition and Mergers:
- 8.2.5.2 Partnerships, Collaborations and Agreements:
- 8.2.5.3 Approvals and Trials:
- 8.3 Sanofi S.A.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Segmental and Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
- 8.3.5.1 Partnerships, Collaborations, and Agreements:
- 8.3.5.2 Trials and Approvals:
- 8.3.5.3 Acquisitions and Mergers:
- 8.4 AbbVie, Inc.
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expense
- 8.4.5 Recent strategies and developments:
- 8.4.5.1 Acquisition and Mergers:
- 8.4.5.2 Approvals & Trials:
- 8.5 Teva Pharmaceutical Industries Ltd.
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
- 8.5.5.1 Product Launches and Product Expansions:
- 8.6 Lupin Limited
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Recent strategies and developments:
- 8.6.3.1 Product Launches and Product Expansions:
- 8.7 Amgen, Inc.
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Regional Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 Recent strategies and developments:
- 8.7.5.1 Trials and Approvals:
- 8.8 Takeda Pharmaceutical Company Limited
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
- 8.8.5.1 Approvals & Trials:
- 8.9 Pfizer, Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Regional & Segmental Analysis
- 8.9.4 Research & Development Expense
- 8.9.5 Recent strategies and developments:
- 8.9.5.1 Approvals & Trials:
- 8.9.5.2 Acquisition and Mergers:
- 8.10. Novartis AG
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Research & Development Expense
- 8.10.4 Recent strategies and developments:
- 8.10.4.1 Partnerships, Collaborations, and Agreements:
- 8.10.4.2 Approvals & Trials:
